Discounted Cash Flow (DCF) Analysis Unlevered

ChemoCentryx Inc (CCXI)

$ 10.75
-0.22 (-2.01%)

Operating Data

Year
A/P
2013
Actual
2014
Projected
2015
Projected
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 6.06------------
Revenue (%)
EBITDA -38.54------------
EBITDA (%)
EBIT -39.11------------
EBIT (%)
Depreciation 0.58------------
Depreciation (%)

Balance Sheet Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash 133.31------------
Total Cash (%)
Account Receivables 0.39------------
Account Receivables (%)
Inventories -------------
Inventories (%)
Accounts Payable 0.91------------
Accounts Payable (%)
Capital Expenditure -0.55------------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 10.75
Beta 1.384
Diluted Shares Outstanding 65.69
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 13.476
Total Debt 24.40
Total Equity 706.15
Total Capital 730.55
Debt Weighting 3.34
Equity Weighting 96.66
Wacc

Build Up Free Cash

Year
A/P
2013
Actual
2014
Projected
2015
Projected
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 6.06------------
EBITDA -38.54------------
EBIT -39.11------------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -39.11------------
Depreciation 0.58------------
Accounts Receivable -------------
Inventories -------------
Accounts Payable -------------
Capital Expenditure -0.55-0.35-0.22-0.30-0.72-0.84-0.79-15.41-----
UFCF -39.09------------
WACC
PV UFCF ------------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 13.19
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -7.90
Equity Value -
Shares Outstanding 65.69
Equity Value Per Share -